Last reviewed · How we verify
NCT07136727: GCOG-CG001
AI-Assisted Comprehensive Management for Cancer Patients With Comorbidities (GCOG-CG001)
NA trial testing AI-assisted comprehensive management system in Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition) in 5,000 participants. Not yet recruiting.
1 May 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xinxiang Medical College |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 5,000 |
| Start date | 15 August 2025 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 May 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- AI-assisted comprehensive management system
Conditions studied
- Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition) — all drugs for Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition) →
Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Who can join
18 and older, any sex, with Oncological Comorbidities (e. g. Hypertension, Diabetes, Malnutrition). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Combined with the digital whole process management data pool, a multi-modal data fusion framework is developed, and an AI model is established to realize risk stratification and personalized treatment Recommendation and dynamic prognosis prediction; validation of whole-process management based on multimodal digital fusion AI-aided decision support system through prospective non-randomized controlled interventional study The effect on survival, complication control and utilization of medical resources in patients with comorbid malignant tumors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07136727
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Affiliated Hospital of Xinxiang Medical College trials
Trials by the same sponsor.
- NCT07530016 — Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma · NA · not yet recruiting
- NCT07530003 — HUMSCs Combined With Col I to Third-Degree Burn Wound · Phase 1, PHASE2 · recruiting
- NCT07347496 — A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined · Phase 4 · not yet recruiting
- NCT07476534 — Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression · not yet recruiting
- NCT07376577 — Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07136727 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xinxiang Medical College
- Last refreshed: 22 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07136727.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing